Document is current
Any future updates will be listed below
-
Authors
Ramgopal, Moti N.
Lalezari, Jacob P.
Pires dos Santos, Ana Gabriela
Krishnan, Preethi
Vaidya, Tanaya R. https://orcid.org/0000-0001-6340-1387
Zhou, Fei
Betman, Heide
Dorr, Patrick
Mostafa, Nael M.
Alcaide, Maria L.
Felizarta, Franco https://orcid.org/0000-0002-3449-7233
Routy, Jean-Pierre https://orcid.org/0000-0001-9897-7589
- License Information
-
More Information
Article History
Received: 18 October 2024
Accepted: 29 August 2025
First Online: 15 October 2025
Competing interests
: M.N.R. is a speaker for AbbVie, Gilead Sciences and ViiV Healthcare and is a consultant for Gilead Sciences, ViiV Healthcare, Merck and Abbott. J.P.L. has no disclosures to declare. A.G.P.d.S., P.K., T.R.V., F.Z., H.B., P.D. and N.M.M. are employees of AbbVie and may own stock and/or stock options. M.L.A. sits on the Gilead Sciences advisory board. F.F. is a speaker and consultant for AbbVie, Gilead Sciences, Merck & Co. and ViiV Healthcare. J.P.R. is a speaker and consultant for AbbVie, Gilead Sciences, Merck & Co., Moderna and ViiV Healthcare and is partially supported for research infrastructure from the Canadian HIV cure entreprise 3.0 (CIHR: BR4-197730).
